New, exclusive capability will allow antibody discovery clients to access more hits and more screening data than competing technologies

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells.

The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making.

“This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president of Antibody Solutions. “Now, we can capture the entire antigen-specific B-cell repertoire from an immune host by using the hybridoma, memory B-cell, and new plasma B-cell discovery pathways, and get vetted sequences from those pathways. There’s incredible value in being able to combine sequence-based and function-based screening from essentially any cell that’s secreting an antibody.”

The new service will leverage a proprietary technology that has the capacity to interrogate, in a single run, more plasma B-cells than current competing technologies. During a run, it can screen antibodies against both soluble antigens and target cells simultaneously, and its AI-driven screening software can rank hits, define multiple unique phenotypes, and prioritize clones for recovery. In addition, fast set-up and processing times allow for greater than 1 million assays to be run in a single workday, making it ideal for difficult targets that demand maximum throughput with a broad range of parameters.

Antibody Solutions’ clients can begin using plasma B-cell discovery services immediately. Included in each project will be the optimization of analysis conditions, a high-throughput multiparameter screen, recovery of paired heavy and light chain sequences and analysis, high-throughput re-expression, and subsequent analysis including ELISA, Flow Cytometry, and BLI for the validation of antibody binding to the target(s) of interest.

“We’re confident that our antibody discovery platform can deliver high-quality inputs that will be perfectly tailored to generate the best outputs,” said Kenney. “We can now exploit all populations of antigen-stimulated B-cells to discover novel antibody therapeutics. We’re excited to bring Cellestive to a new level and offer truly comprehensive solutions to our clients’ antibody discovery needs.”

About Antibody Solutions

Antibody Solutions empowers companies to advance their discovery by delivering fit-for-purpose antibodies. Their Cellestive platform provides comprehensive discovery services with a fee-for-service, pay-as-you-go business model. With a long-standing reputation and a time-tested discovery process, Antibody Solutions has served more than 800 clients since 1995. Headquartered in Santa Clara, CA they serve clients worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422788172/en/

For Antibody Solutions:
Debra Valsamis | Business Development Manager
dvalsamis@antibody.com
(650) 938-4300 x111

Logo

Tags

More Like This

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Proteintech Genomics Launches First Commercially Available Solution for the Detection of Intracellular Proteins for Single-Cell RNAseq Experiments

BioMed X Launches a New Call for Application in Autoimmune Disease Research

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research

Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress